Talazoparib, another potent PARP inhibitor, was approved based on a Phase I trial (NCT03499353), which reported a median overall survival (OS) of 24.3 months in HER2‐negative advanced breast cancer patients, significantly outperforming the 6.3 months observed in those receiving standard chemotherapy. Here, PARP1 is linked to breast carcinoma.